-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The third batch of national collection has been completed, according to the announcement of listed companies, statistics of 44 third batch of selected drugs in the consistent evaluation of research and development (including the same adoption) costs, a total of 487 million yuan.
Without taking into account its past revenues and other costs incurred in the production and marketing process, eight of the 44 drugs included in the statistics would need to sell at least 100 million tablets (to the main specification) to recover costs.
Among them, Enhua Pharmaceutical's chlorine nitrogen tablets at the price of 0.016 yuan / tablet, according to its announced 6.68 million yuan consistency evaluation costs, need to sell 42.278 million tablets to recover the cost, about 4.2278 million boxes (size packaging 25mg x 100 tablets).
Jianmin Pharmaceuticals' left ethyl laxitan oral solution was approved for sale in April 2020 according to the new 4 categories, the investment in research and development costs of about 19.82 million yuan, so far the variety has not yet achieved sales.
Jianmin Pharmaceuticals announcement shows that its first-year revenue of the variety according to the expected number of selected products is about 11.93 million yuan, if only by the selected region is not enough to recover research and development costs in the first year.
According to the announcement of the proposed winning bid for products issued by some listed companies, Fosun Pharmaceuticals subsidiary Wanbang Biocomputer's non-busta tablets and pivastatin calcium tablets reached sales of 1.126 billion yuan and 476 million yuan in 2019, respectively, and the two products were reduced by 92% and 89% respectively, with the first year's agreed winning amount of revenue of 48.07 million yuan and 17.1 million yuan, respectively.
On the other hand, in this collection, there are some of the winning products on August 19 to obtain the approval of the State Drug Administration to list, such as Jiayi Pharmaceutical's apixaban tablets, Haizheng Pharmaceutical's Tegrelo tablets and so on.
, Haizheng Pharmaceuticals for Grelo tablets according to the new 4 categories approved for listing, research and development investment of 28.14 million yuan, after the winning bid, the first year agreed to the number of winning revenue will reach 30.21 million yuan.
.